Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications

Mirimus Inc has collaborated with Biogen Inc BIIB to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
Terms of the collaboration are not disclosed.
Under the agreement, Mirimus will engineer RNAi-based therapeutics that Biogen will assess to determine feasibility in potential neurological disease settings.
If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).
Price Action: BIIB shares are down 0.75% at $320.06 during the market session on the last check Wednesday.